The COVID-19 pandemic has been humbling for the biomedical community, pointing out as much about what we do not know as what we do. Among these learnings are lessons about immune-based measures to prevent or treat a new biothreat. This article summarizes lessons learned from two experimental approaches for passive immunity, convalescent plasma and monoclonal antibody therapy. Two early reports of outcomes, both of which appeared within hours of one another, reveal the importance of blending past learning with a forward-looking approach. These also present cautionary lessons as the world looks to new vaccines to help eradicate this deadly scourge.

Original languageEnglish
Pages (from-to)1035-1036
Number of pages2
JournalACS Pharmacology and Translational Science
Issue number5
StatePublished - Oct 9 2020


  • COVID-19
  • SARS-CoV2
  • convalescent plasma
  • monoclonal antibody
  • vaccine


Dive into the research topics of 'Oh, the Frustration of Antibodies!'. Together they form a unique fingerprint.

Cite this